# Urania Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/urania-therapeutics

- Industry: Pharmaceuticals
- Headquarters: France
- Website: www.uraniatx.com
- Total disclosed funding: $3.8M
- Latest round: Series A (Jul 15, 2021)
- Investors on record: 3

## About

Urania Therapeutics focuses on developing innovative treatments for genetic diseases and cancers by targeting nonsense mutations, offering potential breakthroughs in previously untreatable conditions.Founded in 2015 and headquartered in France, Urania Therapeutics develops therapies specifically designed to address genetic diseases associated with nonsense mutations. The company has undergone strategic pivots to enhance its focus on READTHROUGH compounds. It has successfully raised EUR 789,500 in a Series A funding round led by NovAliX and Capital Grand Est, with a total amount raised of EUR 789,500 by July 2021. The current valuation of the company stands at EUR 4.382 mn.Urania Therapeutics specializes in developing innovative treatments for genetic diseases and cancers resulting from nonsense mutations. The company focuses on creating READTHROUGH compounds, which aim to restore the synthesis of full-length proteins by bypassing deleterious mutations via a gene-independent mechanism at the ribosomal level. This approach addresses a significant therapeutic gap in monogenic diseases, which collectively affect around 300 million people globally. Urania's primary customer base includes hospitals and healthcare providers that serve patients suffering from these genetic conditions, particularly those with nonsense mutations that account for 10-15% of cases. The company's products are positioned for markets in Europe and North America, where there is an increasing demand for groundbreaking therapies that address previously untreatable genetic disorders.Urania Therapeutics generates revenue through partnerships and collaborations with research institutions, pharmaceutical companies, and healthcare providers focused on rare disease treatments. The company’s business model may involve licensing agreements for their READTHROUGH compounds, which would allow partners access to their proprietary drug candidates in exchange for upfront fees and royalties on future sales. Additionally, Urania may engage in grant-funded research initiatives to support their R&D activities while bolstering their financial foundation. The transactions typically revolve around collaborative development agreements, where Urania's innovative drug designs are integrated into broader therapeutic pipelines, facilitating commercialization efforts in exchange for revenue-sharing agreements. Specific pricing structures for their products are aligned with the specialized nature of the treatments they offer, catering to a niche market with high unmet medical needs.Urania Therapeutics plans to leverage the EUR 789,500 raised in July 2021 to advance the development of their READTHROUGH compounds. The company is focused on launching new products aimed at treating genetic diseases caused by nonsense mutations, targeting a market launch by 2023. Moreover, Urania aims to expand its presence in European and North American markets, aiming to establish strategic partnerships within these regions to enhance its distribution capabilities. These initiatives are designed to position the company favorably in addressing the significant unmet needs of patients suffering from genetic disorders.

## Funding rounds

- Series A, Jul 15, 2021, $0.9M — Capital Grand Est, NovAliX
- Series A, Sep 11, 2020, $1.9M — Capital Grand Est, NovAliX, AdBio Partners
- Series A, Nov 29, 2019, $0.9M — NovAliX, AdBio Partners

## Investors

- NovAliX — Series A
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series A
- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Series A